Edwards Acquires 2 Heart Device Company’s

In an effort to increase the number of structural heart products it offers, Edwards Lifesciences announced that it will spend around $1.2 billion to purchase two cardiac device startups.

The purchases are being made at the same time as Edwards, which specialises in transcatheter aortic valve replacement (TAVR), reported lower-than-expected revenue growth in Q2.

Edwards said that it has reached an agreement to purchase JenaValve Technology, which is creating the first aortic regurgitation therapy. Edwards projects that the JenaValve Trilogy heart valve system will receive FDA certification in late 2025.

Additionally, the business activated its option to purchase Endotronix, a new therapeutic region for the business that makes an implanted pulmonary artery pressure sensor for heart failure.

If specific milestones are met, Edwards anticipates paying an extra amount of up to $445 million, the firm stated in a regulatory filing. According to Edwards, the investments offer substantial growth potential in areas with limited services.